From Figs 5 and 7 we see that anti-TGF-β is the most effective drug to slow the IPF progression (with A = B = 0.1) and anti-IL-13 has only very mild benefits (with B3 = 1). The gene discussed is TGFB1; the disease is idiopathic pulmonary fibrosis.